Wedbush Securities’s aTyr Pharma ATYR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
– Sell
-120
Closed -$25K – 1029
2019
Q2
$25K Buy
120
+74
+161% +$20.1K ﹤0.01% 970
2019
Q1
$14K Buy
+46
New +$13.1K ﹤0.01% 917
2018
Q3
– Sell
-42
Closed -$21K – 945
2018
Q2
$21K Buy
+42
New +$39.8K ﹤0.01% 865
2017
Q1
– Sell
-25
Closed -$30K – 888
2016
Q4
$30K Buy
+25
New +$41K ﹤0.01% 796
2016
Q3
– Sell
-22
Closed -$35K – 871
2016
Q2
$35K Buy
+22
New +$40.9K 0.01% 749

Other funds holding ATYR

Wedbush Securities's ATYR Position: Q3 2019 in Review

Wedbush Securities sold out of aTyr Pharma (ATYR) in Q3 2019, closing a stake of 120 shares — an estimated $25K sold.

Wedbush Securities first reported a position in ATYR in Q2 2016 and held it in 5 quarters. The position peaked at $35K in Q2 2016. 18 funds tracked by Wall St. Rank hold ATYR as of Q3 2019.

  • Wedbush Securities reported no remaining aTyr Pharma position as of Q3 2019 after selling out during the quarter.
  • Wedbush Securities sold 120 aTyr Pharma shares in Q3 2019, an estimated $25K.
  • Wedbush Securities first reported a position in aTyr Pharma in Q2 2016 and held it in 5 quarters.
  • Wedbush Securities's aTyr Pharma position peaked at $35K in Q2 2016.
  • 18 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2019.

Based on Wedbush Securities's 13F filing for Q3 2019, filed 17 Oct 2019.